Mather Group’s Cue Biopharma CUE Stock Holding History

Mather Group’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$854	Hold	33	–	–	﹤0.01%	2163
2026 Q2	$1.04K	Hold	33	–	–	﹤0.01%	1797
2026 Q1	$230	Buy	+33	New	+$308	﹤0.01%	1842
2025 Q4	–	Sell	-33	Closed	-$719	–	868
2025 Q3	$719	Buy	+33	New	+$774	﹤0.01%	1602
2025 Q2	–	Sell	-33	Closed	-$911	–	858
2025 Q1	$911	Buy	+33	New	+$1.23K	﹤0.01%	1646

Mather Group's CUE Position: Q3 2026 in Review

Mather Group held its Cue Biopharma (CUE) position steady in Q3 2026 at 33 shares worth $854. The position accounts for ﹤0.01% of the portfolio, ranked #2163.

Mather Group first reported a position in CUE in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.04K in Q2 2026. 1 fund tracked by Wall St. Rank holds CUE as of Q3 2026.

Mather Group held 33 shares of Cue Biopharma worth $854 as of Q3 2026.
Mather Group left its Cue Biopharma share count unchanged in Q3 2026.
Cue Biopharma made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #2163 holding.
Mather Group first reported a position in Cue Biopharma in Q1 2025 and has held it in 5 quarters since.
Mather Group's Cue Biopharma position peaked at $1.04K in Q2 2026.
1 fund tracked by Wall St. Rank held Cue Biopharma as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.